Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire - Mon Jun 1, 3:01PM CDT

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...

KROS : 10.55 (-3.21%)
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results GlobeNewswire - Thu May 14, 7:00AM CDT

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference GlobeNewswire - Mon Mar 9, 7:00AM CDT

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS GlobeNewswire - Mon Mar 9, 7:00AM CDT

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Wed Mar 4, 3:01PM CST

LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)
Keros Therapeutics Appoints Charles Newton to its Board of Directors GlobeNewswire - Thu Feb 26, 3:01PM CST

LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences GlobeNewswire - Wed Feb 18, 3:01PM CST

LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)
Keros Therapeutics Announces Final Results of Tender Offer GlobeNewswire - Thu Nov 20, 2025

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender...

KROS : 10.55 (-3.21%)
Keros Therapeutics Announces Preliminary Results of Tender Offer GlobeNewswire - Wed Nov 19, 2025

LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender...

KROS : 10.55 (-3.21%)
Keros Therapeutics Reports Third Quarter 2025 Financial Results GlobeNewswire - Wed Nov 5, 2025

LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...

KROS : 10.55 (-3.21%)

Barchart Exclusives

This Dividend Stock Has Rebounded as ‘AI-Pocalypse’ Fears Subside. Buy It Now. Barchart - Tue Jun 2, 6:30PM CDT
Accenture stock has recovered from its 2026 lows as "AI-pocalypse" fears have somewhat subsided. Can the stock continue to rise further? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.